ZimVie has agreed to be acquired by an affiliate of the healthcare investment firm Archimed for $19 per share in cash, valuing the company at approximately $730 million. The offer reflects a 99% premium over ZimVie’s 90-day volume-weighted average price.
The board of directors unanimously approved the transaction, expected to close by the end of 2025, pending regulatory and shareholder approvals. ZimVie retains the right to solicit superior offers through August 29.
CEO Vafa Jamali highlighted the deal as a milestone for ZimVie, emphasizing Archimed’s potential to support the company’s global expansion in dental technology. If completed, ZimVie will become a private company and be delisted from Nasdaq.
The deal follows ZimVie’s 2023 sale of its spine unit to H.I.G. Capital for $375 million. Archimed Managing Partner André-Michel Ballester called ZimVie’s fundamentals “strong” and its growth “compelling.”
Follow MEDWIRE.AI for the latest on MedTech mergers and acquisitions.
